Autumn officially begins tomorrow, so whether you spend your weekend watching football, picking apples, or indulging in some pumpkin pie, make sure you leave room for our Research Ethics Roundup. This week’s installment features articles on recent protests over genetically modified organisms (GMOs) in China, the human side of clinical trials, and more!
Research Ethics Roundup: Questioning post-market trials, stem cell research, and more!
Tags:Though summer may be nearly over, the world of research ethics is still heating up. From the ethical implications of post-market research, to the protection of children in clinical trials, this week’s Research Ethics Roundup is full of stories you won’t want to miss.
Additional protections for children who participate in clinical research: In this powerful opinion piece, pediatric ethicist and PRIM&R faculty member, [...] Read more
Research Ethics Roundup: Examining the nocebo effect, new clinical trial rules in India, and more!
Tags:
India plans to reform oversight of medical research, while Harvard University agrees to restructure their Primate Center. Learn about these changes and more in this week’s Research Ethics Roundup!
Testing what we think we know: This opinion piece from The New York Times posits that researchers ought to spend less time investigating novel technologies, and more time evaluating whether standard treatments are actually effective and efficient.
Research Ethics Roundup: The latest on the H5N1 moratorium, regulating online research, and more!
Tags:
In this week’s Research Ethics Roundup, hear the latest developments in the H5N1 debate, explore one doctor’s plan to minimize research misconduct, and learn about a recent study that found that some physicians may be doing research for all the wrong reasons.
Private-sector physicians run clinical trials mostly for the money, study finds: There has been a dramatic shift in those conducting most clinical trials from academically-affiliated physicians to private-sector physicians. A new study suggests this shift might be the result of big money’s influence over medical research, with many doctors thinking of trials as business ventures rather than scientific endeavors. <[...] Read more
by Joan Rachlin, JD, MPH, Executive Director
Last week’s Food and Drug Administration approval of Truvada, the first drug to help prevent HIV infection in high-risk populations, was extraordinary, and extraordinarily well-timed. The announcement coincided with the opening of the 2012 International AIDS Conference, which was held in the US for the first time since President Obama lifted a travel and [...] Read more